Kaneko Koichi
Division of Neuropsychiatry, Department of Brain and Neurosciences, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.
Yonago Acta Med. 2018 Jun 18;61(2):91-102. doi: 10.33160/yam.2018.06.001. eCollection 2018 Jun.
Schizophrenia is a chronic, disabling disorder, which commonly emerges in adolescence and young adulthood. While pharmacological treatment with currently available second-generation antipsychotics exerts beneficial effects on the positive symptoms of schizophrenia, they have little effect on negative symptoms or cognitive deficits. Because these two types of symptoms are enduring, and negatively impact social functioning throughout the course of the illness, there is an urgent requirement to develop new effective therapeutic approaches to manage them. Negative symptoms have proven difficult to assess accurately because of their complexity, even with commonly used clinical rating scales such as the Scales for Assessment of Negative Symptoms (SANS). In this context, new "next-generation" assessment tools have recently been developed, which include items representing the five domains encompassed by the two established clusters of negative symptoms (diminished expression and avolition), and enable the detection of changes in severity. Despite various therapeutic approaches to alleviating negative symptoms, there are currently no established methods available for clinical practice. Cognitive deficits are also a core feature in the majority of people with schizophrenia, with impaired performance observed across many cognitive domains, including verbal memory, working memory, attention, and executive functions. Such cognitive deficits are likely associated with either reduced or inefficient function of related distributed neural networks. Psychosocial treatments for cognitive impairments in schizophrenia seem promising given the beneficial effects of cognitive remediation therapy on such impairments, as well as on social functioning, as substantiated in several meta-analytic studies with modest effect sizes. Furthermore, using functional neuroimaging techniques, the size of these therapy-induced beneficial changes in neurocognitive performance has been demonstrated to be correlated with the degree of the changes in brain activation during performing some cognitive tasks in the prefrontal and temporal cortices. This suggests neurobiological effects are exerted by psychosocial cognitive remediation treatments.
精神分裂症是一种慢性致残性疾病,通常在青少年期和成年早期出现。虽然目前使用的第二代抗精神病药物进行药物治疗对精神分裂症的阳性症状有有益影响,但对阴性症状或认知缺陷几乎没有作用。由于这两种症状持续存在,并在疾病过程中对社会功能产生负面影响,因此迫切需要开发新的有效治疗方法来管理它们。事实证明,阴性症状由于其复杂性难以准确评估,即使使用常用的临床评定量表,如阴性症状评定量表(SANS)。在这种背景下,最近开发了新的“下一代”评估工具,其中包括代表由两个既定的阴性症状集群(表达减少和意志缺乏)所涵盖的五个领域的项目,并能够检测严重程度的变化。尽管有各种减轻阴性症状的治疗方法,但目前尚无既定的临床实践方法。认知缺陷也是大多数精神分裂症患者的核心特征,在许多认知领域都观察到表现受损,包括言语记忆、工作记忆、注意力和执行功能。这种认知缺陷可能与相关分布式神经网络的功能降低或效率低下有关。鉴于认知康复治疗对精神分裂症认知障碍以及社会功能有有益影响,如在几项效应量适中的荟萃分析研究中所证实的那样,针对精神分裂症认知障碍的心理社会治疗似乎很有前景。此外,使用功能神经成像技术已证明,这些治疗引起的神经认知表现的有益变化的大小与前额叶和颞叶皮质在执行某些认知任务期间大脑激活的变化程度相关。这表明心理社会认知康复治疗具有神经生物学效应。